Research programme: small molecule anticancer therapeutics - Telik

Alternative Names: 8967; EAAF; TLK 60357; TLK 60596

Latest Information Update: 16 Mar 2012

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Telik
Class Small molecules
Mechanism of Action Microtubule protein modulators; Signal transducing adaptor protein inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

31 Dec 2011 Suspended - Preclinical for Cancer in USA (PO)
30 Jun 2010 This programme is still in active development
16 Apr 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com